SURYA PHARMACEUTICAL LIMITED

REGD. OFFICE: 911, 9th Floor, Surya Kiran Building, K.G. Marg, New Delhi
CORP. OFFICE: SCO 164-165, SECTOR 9-C, CHANDIGARH

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED DECEMBER 31, 2010

(Rs. In Millions)

Sr. No.	Particulars	Quarter ended		Nine Months Ended		Year Ended
		31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/Income from Operations	3980.89	2980.85	11524.95	7789.11	11341.35
	Total	**3980.89**	**2980.85**	**11524.95**	**7789.11**	**11341.35**
2	Expenditure					
	a. increase/decrease in Stock in Trade and Work in progress	(919.52)	(338.49)	(2263.35)	(1052.20)	(2168.40)
	b. Consumption of Raw Materials	3965.79	2683.14	11148.37	7080.74	11027.76
	c. Employees' cost	104.14	72.33	288.19	190.33	288.33
	d. Depreciation	77.54	52.92	227.73	158.53	205.55
	e. Other Expenditure	163.38	117.80	551.64	368.40	564.84
	f. Total	**3391.33**	**2587.70**	**9952.58**	**6745.80**	**9918.08**
3	Profit from Operations before Other Income,	589.56	393.15	1572.37	1043.31	1423.27
	Interest & Exceptional Items (1-2)					
4	Other Operating Income	13.98	21.52	54.56	56.93	104.98
5	Profit before Interest & Exceptional Items (3+4)	603.54	414.67	1626.93	1100.25	1528.25
6	Interest	253.61	156.69	663.86	451.81	623.62
7	Profit after Interest but before Exceptional Items (5-6)	349.93	257.98	963.07	648.44	904.63
8	Exceptional Items					
9	**Profit from Ordinary Activities before tax (7+8)**	**349.93**	**257.98**	**963.07**	**648.44**	**904.63**
10	Tax expense	69.74	43.83	191.94	110.17	144.03
11	**Net Profit from Ordinary Activities after tax (9-10)**	**280.19**	**214.15**	**771.13**	**538.27**	**760.61**
12	Extraordinary Items					
13	**Net Profit for the period (11-12)**	**280.19**	**214.15**	**771.13**	**538.27**	**760.61**
14	Paid-up Equity Share Capital (Face Value of Rs.1/- per Share)	183.25	144.68	183.25	144.68	144.68
15	Reserves excluding Revaluation Reserves					2887.20
16	Earnings Per Share (EPS)					
	a. Basic and diluted EPS before Extraordinary items	1.53	1.48	4.21	3.72	5.26
	b. Basic and diluted EPS after Extraordinary items	1.53	1.48	4.21	3.72	5.26
17	Public Shareholding					
	- Number of Shares	125488750	8900475	125488750	8900475	8691975
	- Percentage of Shareholding	68.48	61.52	68.48	61.52	60.08
18	Promoter and Promoter Group Shareholding:					
	a) Pledged/Encumbered	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered					
	- No. of Shares	57763630	5567863	57763630	5567863	5776363
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100	100	100	100	100
	- Percentage of Shares (as a % of the total share Capital of the Company)	31.52	38.48	31.52	38.48	39.92

NOTES:

1. The above results have been reviewed by the Audit Committee on 03.02.2011 and taken on record by the Board of Directors at its meeting held on 03.02.2011
2. The above results have undergone Limited Review by the Statutory Auditors of the Company.
3. There was no pending Investor's Complaint as on 31.12.2010
4. Other Expediture includes Loss on Derivative Trading of Rs 101.77 Lacs(Net of Profit) during the period under review.
5. During the quarter under review, Equity shares of the Company of the face value of Rs.10/- each have been sub-divided into 10 equity shares of face value of Re.1/- each.
6. During the quarter under review, Company' s wholly owned subsidiary, Surya Pharmaceutical (Singapore) Pte Ltd has acquired OTC Pharma Brands including a leading topical analgesic Brand, ACTIVON and their current marketing operations through large drugstore retailing like Walmart, Walgreen, CVS etc. in USA.
7. Surya Healthcare Limited, Company's subsidiary, Operates in Pharmacy Retail Segment and has 102 Retail Stores under Brand Name "VIVA" as on the date of Board's Meeting and now has presence in 4 States and one Union Territory covering 14 Cities.
8. Provision for Deferred tax liability as per AS 22 will be made in the Audited Results.
9. The Company operates in only one segment.
10. Figures have been regrouped/rearranged wherever considered necessary.

For and on behalf of the Board of Directors
For Surya Pharmaceutical Limited

RAJIV GOYAL
(Managing Director)

3rd Feb, 2011
Chandigarh